If one is developing a drug-drug combo product with EU registration intended to proceed via the decentralized procedure, does it ever make any sense to seek scientific advice from the EMA?
Thank you
-------------------------------------------
Heimo Scheer PhD
Vice President, Regulatory Affairs
Celerion
Somerville MA
United States
-------------------------------------------